PepRank

GHRP-6

Also: growth hormone-releasing hexapeptide · CIGB-500 (Cuban development code)

MetabolicRecoveryInjection

First-generation GHRP used as an appetite drug for bulking; strong hunger, cortisol, glucose, GH axis.

Safety tier
Avoid
strict bar
Positive
59%
of 14 reports
Per month
≈ €13–81
estimate
Rank
#25
of 61 research peptides

At a glance

Access
Grey market
InjectionFelt in 10–20 min, lasts 1–2 h
Strict case
GH/IGF-1 axis elevation plus cortisol rise and reduced insulin sensitivity (FDA), with only single-dose human safety data.
Best effects
Strong hunger within 10-20 minutes · weight gain when used for bulking · faster gastric emptying · acute GH and IGF-1 rise
Downsides
Nausea, flushing and sweating for 10-15 minutes after injection · heavy sweating and overheating when injected fasted · sleep disruption for some · effect fades within weeks for some users
Typical use
Users: 100-200 mcg subq 2-3x/day, 20-30 minutes before meals, on an empty stomach; some titrate to 300 mcg. Trials used 1 mcg/kg IV boluses or infusions.
Stacked with
Stacked with
CJC-1295 / mod-GRF(1-29): Paired for a larger GH pulse, usually before meals. · MK-677: Combined by people chasing more appetite; both act on the ghrelin receptor and both raise glucose. · Retatrutide: Used by some on GLP-1/triple agonists who want weight maintenance or gain rather than loss.

Safety

Watch
GH/IGF-1 axis elevation (glucose, theoretical neoplasm promotion) · FDA category 2 (2023): potential cortisol effect and raised blood glucose from reduced insulin sensitivity · Not GH-selective: FDA notes a cortisol effect, and its super-analogues GHRP-2 and hexarelin raise prolactin and ACTH too · Grey-market vials: aggregation and impurity immunogenicity concerns (FDA)
Tier by safety barStrict AvoidBalanced CautionEvidence only Caution
  • Seen harm0 of 3
  • Mechanism2 of 3
  • Data gap2 of 3
  • Silent harm3 of 3
  • Product3 of 3
Never if
Pregnancy or breastfeeding (no human reproductive data) · Active or past cancer · Diabetes, prediabetes or insulin resistance · Pituitary tumours, including prolactinoma · Cushing's syndrome or other cortisol excess · Current or past eating disorder (used specifically to force hunger) · Under 18
Why each score
Seen harm 0/3
No published case reports, label warnings or trial SAE signals: an 18-man single-dose escalation to 400 mcg/kg IV had 23 mild adverse events and none serious, and a 9-man pharmacokinetic study reported none. FDA's 2023 note lists only cortisol and glucose effects, not events. Reddit reports are transient nausea, flushing, sweating and poor sleep. The zero reflects how little documented exposure there is, despite decades of bodybuilding use, not reassurance. Selman-Housein et al. 2014: phase I safety of GHRP-6 (CIGB-500) in 18 healthy men ↗Cabrales et al. 2013: GHRP-6 pharmacokinetics in nine healthy men ↗FDA category 2 bulk substances: GHRP-6 ↗
Mechanism 2/3
Hormone-axis activation: a 34-hour infusion doubled GH output and raised IGF-1 by about a quarter, and FDA cites a cortisol effect and reduced insulin sensitivity. Its super-analogues GHRP-2 and hexarelin also release prolactin and ACTH. The IGF-1 cancer association is epidemiological, with no in-vivo demonstration of harm from GHRP-6, so 2. Jaffe et al. 1993: prolonged GHRP-6 infusion raises GH and IGF-1 ↗FDA category 2 bulk substances: GHRP-6 (cortisol, glucose) ↗Renehan et al. 2004: IGF-I and cancer risk (Lancet) ↗
Data gap 2/3
Never approved. Human data are small pharmacology studies of 9-18 healthy young men given single IV doses or a day-long infusion; there are no repeated-dose trials of the subcutaneous use people actually do. Selman-Housein et al. 2014: phase I, 18 men, single doses ↗Jaffe et al. 1993: 34-hour infusion in nine men ↗
Silent harm 3/3
The feared harms are theoretical IGF-1-driven tumour promotion (3 under the rubric) and creeping insulin resistance that only shows on glucose or HbA1c testing (a 2). The hunger, sweating and flushing users notice are immediate but not the concern. Renehan et al. 2004: IGF-I and cancer risk ↗
Product 3/3
Bought as grey-market injectable vials or cheap 10-vial kits, reconstituted at home and injected 2-3 times a day. FDA flags aggregation and impurity immunogenicity for compounded GHRP-6. FDA category 2 bulk substances: GHRP-6 (immunogenicity) ↗Mendias & Awan 2026 preprint: grey-market peptide quality ↗

User reports

All 14 reports →
Users report
Fourteen reports, almost all from people using it to gain weight. The hunger spike is the reliable effect: within 10-20 minutes at 200 mcg, with users eating 500-800 extra kcal and reporting 8 lb in 4-6 weeks (one claims 48 to 67 kg). It is weaker or absent at 100-150 mcg for some, and two very lean users felt no appetite change at all. Side effects are transient nausea, flushing and heavy sweating after fasted shots; one long-time user says it wrecks his sleep. Lifters compare it unfavourably with ipamorelin for anything but appetite. Felt nothing: 2 of 14 reports felt no appetite effect (at 150-200 mcg), and one more says the effect faded after two weeks..
Glowing 1Positive 8Mixed 2Nothing 2Negative 1
  • r/Biohacking· · 1 upvotesOriginal ↗

    Woog ook 48kg weeg nu 67kg deed 2 keer per dag spuiten 100 mcg per keer 20 min voor het eten

    GlowingMetabolic · 100 mcg 2x/day, 20 minutes before meals · Injection

    Dutch-language comment; duration and training not stated

  • r/bodybuilding· · 2 upvotesOriginal ↗

    I've had a prescription for it for years. Works well IMO. Doesn't really contribute to gains as much as keep you lean.

    PositiveMetabolic · Injection · years

    says it was prescribed

  • r/Biohacking· · 1 upvotesOriginal ↗

    I took like 150mcg and didn’t get hungry

    NothingMetabolic · 150 mcg · Injection

Studies

Evidence
Small human studies — Pharmacology only (infusion, pharmacokinetic and single-dose phase I studies of 9-18 men); developed in Cuba for heart-attack cardioprotection, never approved
Caveat
The appetite effect is the only one users reliably notice; muscle and fat-loss claims rest on the GH rise, not on outcome data. Human data stop at single IV doses and day-long infusions in healthy young men.
1 more study and 4 sources

Sources

Sequence

The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.

Report grades

Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.

GlowingPositiveMixedNothingNegativeBad reaction

% positive

The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.

Researcher estimate

No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.

Safety tier

Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.

Safety bar

The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.

Seen harm

Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.

Mechanism

A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.

Data gap

How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.

Silent harm

Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.

Product

The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.

Evidence

The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.

Access

How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.

Price per month

Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.

Dose users report

The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.

Shop trust

Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.

Best value

Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.

Testing

Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.

Added peptide

Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.